PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Docetaxel

Drugs in development · updated 30 October 2026

Docetaxel: clinical trials and development status

Other names and codes: Taxotere, Beizray, Docivyx, Docefrez

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 27 November 1995

As of 30 October 2026 Docetaxel is in 393 active clinical trials (recruiting or ongoing, phases I–III) for 80 diseases. The most advanced phase is III.

393Active trials
IIIMost advanced phase
80Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Docetaxel and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 80 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Non-small-cell lung carcinomaIII74NCT04928846
Breast neoplasmIII50NCT05296798
Prostatic NeoplasmsIII44NCT06925737
Stomach neoplasmIII26NCT06346392
Head and neck squamous cell carcinomaIII25NCT00588770
NeoplasmIII19NCT04928846
Lung neoplasmIII18NCT06635824
MetastasisIII15NCT04685135
Triple-negative breast neoplasmIII12NCT03671044
Bladder neoplasmIII11NCT04579224
Transitional cell carcinomaIII11NCT04579224
Non-muscle invasive bladder neoplasmIII10NCT05538663
AdenocarcinomaIII8NCT06592924
Nasopharyngeal CarcinomaIII7NCT06629597
Ovarian neoplasmIII6NCT05281471
Squamous cell carcinomaIII6NCT06908304
Endometrial neoplasmIII5NCT06340568
Esophageal squamous cell carcinomaIII5NCT06644781
Salivary gland neoplasmIII5NCT00588770
Uterine cervix neoplasmIII5NCT07797153
CarcinomaIII4NCT00565851
Castration-resistant prostatic neoplasmIII4NCT07225946
Esophagus adenocarcinomaIII4NCT06356311
Oropharyngeal NeoplasmsIII4NCT07768189
Fallopian tube neoplasmIII3NCT05281471
Breast ductal carcinomaIII2NCT03201861
Gastrointestinal neoplasmII–III2NCT06028737
Laryngeal diseaseIII2NCT03340896
Laryngeal neoplasmII–III2NCT05063552
VacciniaIII2NCT05281471

Everything on Docetaxel

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch